Question special
Lead Moderator

As briefly touched on previously by Dr. Lanser - the LEAP and LEAP-ON studies were done in a fairly homogenous geographic area with respect to ethnic and/or racial diversity. Further, as noted by Dr. Leung, the strong association between filaggrin mutations and peanut allergy may vary in different geographic locations.

These two factors undoubtedly influence the generalizability of the LEAP-ON results - is a multi-center trial the answer? What other key questions could a multi-center trial answer?